Skip to main content
Precision Gene Therapy for Parkinson’s Disease: Targeted SNCA Down-regulation in Dopaminergic Neurons

Precision Gene Therapy for Parkinson’s Disease: Targeted SNCA Down-regulation in Dopaminergic Neurons

Unmet Need Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affecting approximately 10 million people globally and 1 million in the U.S. PD is characterized by involuntary movements such as tremors, stiffness, and…

Read More

Novel RNA-based anti-cancer therapeutic for sustained immunotherapy by combined pattern recognition receptor (PRR) activation and anti-microRNA therapy (AMT)

Novel RNA-based anti-cancer therapeutic for sustained immunotherapy by combined pattern recognition receptor (PRR) activation and anti-microRNA therapy (AMT)

Unmet Need Cancer is incredibly prevalent and current therapies are insufficient. Globally, lifetime prevalence is 1 in 5, and mortality is 1 in 9 in men and 1 in 12 in women. Solid tumors account…

Read More

Gene therapy for non-alcoholic steatohepatitis and associated liver fibrosis

Gene therapy for non-alcoholic steatohepatitis and associated liver fibrosis

Unmet Need Driven by the rising tide of obesity and lack of medical treatment, it is estimated that 1 out of 4 adults in the US has non-alcoholic fatty liver disease or non-alcoholic steatohepatitis (NAFLD/NASH).…

Read More

CRISPR-based antiviral treatment of coronavirus infections

CRISPR-based antiviral treatment of coronavirus infections

Unmet Need The global market for antiviral drugs is a large one, topping $60B, and is getting larger due to the ongoing COVID-19 pandemic. Spurred on by a $3B investment from the U.S. government into…

Read More

Improving immune checkpoint therapies for cancer by inhibiting the PCSK9 protein

Improving immune checkpoint therapies for cancer by inhibiting the PCSK9 protein

Value Proposition Immune checkpoint inhibitor therapies are exciting new drugs for treatment of cancers. Despite their efficacy for certain cancers, immune checkpoint inhibitors only effective in 10-30% of cancer patients. Because of this, there is…

Read More

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us